J. Goldman & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

J. Goldman & Co’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,496	Closed	-$327K	–	487
2025 Q1	$327K	Sell	13,496 -4	-0%	-$90	0.01%	419
2024 Q4	$282K	Hold	13,500	–	–	0.01%	394
2024 Q3	$268K	Sell	13,500 -6,750	-33%	-$125K	0.01%	399
2024 Q2	$314K	Sell	20,250 -6,142	-23%	-$95.6K	0.01%	389
2024 Q1	$421K	Sell	26,392 -349	-1%	-$5.26K	0.01%	334
2023 Q4	$450K	Buy	26,741 +13,241	+98%	+$181K	0.02%	271
2023 Q3	$158K	Sell	13,500 -513,202	-97%	-$6.86M	0.01%	324
2023 Q2	$7.08M	Buy	526,702 +416,214	+377%	+$5.99M	0.26%	103
2023 Q1	$1.83M	Buy	+110,488	New	+$1.82M	0.07%	212
2020 Q3	–	Sell	-107,951	Closed	-$499K	–	319
2020 Q2	$499K	Sell	107,951 -346,822	-76%	-$1.56M	0.03%	218
2020 Q1	$1.75M	Buy	+454,773	New	+$1.87M	0.21%	112

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

J. Goldman & Co's CPRX Position: Q2 2025 in Review

J. Goldman & Co sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 13,496 shares — an estimated $327K sold.

J. Goldman & Co first reported a position in CPRX in Q1 2020 and held it in 11 quarters. The position peaked at $7.08M in Q2 2023. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

J. Goldman & Co reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
J. Goldman & Co sold 13,496 Catalyst Pharmaceutical shares in Q2 2025, an estimated $327K.
J. Goldman & Co first reported a position in Catalyst Pharmaceutical in Q1 2020 and held it in 11 quarters.
J. Goldman & Co's Catalyst Pharmaceutical position peaked at $7.08M in Q2 2023.
365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.